Introduction
The c-myc protooncogene is a central regulator of key cellular processes, including proliferation, apoptosis, and dierentiation through its interaction with multiple target genes. Due to its critical regulatory functions, expression of c-myc is regulated at the level of transcription, mRNA and protein stability (Potter and Marcu, 1997) . Three major recognized forms of myc include c-myc 2, a 64 kDa major polypeptide initiated at AUG in mammalian cells which is the predominant form; c-myc 1, a 67 kDa longer polypeptide initiated at 15 codons upstream of AUG; and cmyc S, a 45 kDa dominant negative polypeptide which lacks box I, a highly conserved region, as well as most of the N-terminal transactivation domain (reviewed in Dang, 1999) . A second highly conserved region lies within box II, which has been implicated in both transactivation and repression of transcription by cmyc (Li et al., 1994) . Overall, the amino terminal domain of c-myc and these boxes were implicated in the regulation of c-myc stability (Flinn et al., 1998) . Interestingly, despite the lack of box I and most of the transactivation domain, c-myc S exhibits a half-life comparable to that of full-length c-myc, suggesting that other regions are required for the regulation of c-myc protein stability (Chen et al., 2000) . Additionally, although transactivation-defective, c-myc S still retains the ability to regulate proliferation and apoptosis, repress transcription of several speci®c promoters, and rescue the myc null phenotype in ®broblasts with homozygous deletion of c-myc (Spotts et al., 1997; Xiao et al., 1998; Mateyak et al., 1997) .
The c-myc protein has a relatively short half-life of about 20 to 30 min (Salghetti et al., 1999) , which resembles other key cellular regulatory proteins, such as p53 (Fuchs et al., 1998) . The c-myc protein is degraded in a proteasome-dependent manner, and the ubiquitination machinery has been implicated in this process (Ciechanover et al., 1991; Flinn et al., 1998; Gavine et al., 1999; Gregory and Hann, 2000; GrossMesilaty et al., 1998; Salghetti et al., 1999) . The ubiquitin-mediated degradation of the c-myc protein has been demonstrated both in vivo (Salghetti et al., 1999) and in vitro (Ciechanover et al., 1991) . Treatment of mammalian cells with proteasome inhibitors, such as MG132 or LLnL, results in the stabilization and detection of polyubiquitin complexes of exogenous and endogenous c-myc and N-myc (Bonvini et al., 1998) , further implicating the involvement of the 26S proteasome in the ubiquitination and degradation of myc proteins.
Changes in the expression of c-myc are often implicated to have a causative role in development of human cancer. Whereas Human Papillomavirus (HPV) E6-16 (high risk oncoprotein), is able to induce the degradation of N-myc in neuroblastoma cells and of cmyc that was transiently expressed in Cos cells, HPV E6-11 (low risk oncoprotein) failed to do so (GrossMesilaty et al., 1998) . In contrast, signi®cant increases in the half-life of c-myc protein have been observed in several human glioma cell lines (Shindo et al., 1993) , as well as in Burkitt's lymphoma cell lines (Salghetti et al., 1999; Bahram et al., 2000; Gregory and Hann, 2000) pointing to the possible regulation of c-myc stability in a cell-type dependent manner. Since mutation of c-myc is not essential for its stabilization in some Burkitt's lymphoma cells other mechanisms are expected to contribute to the regulation of c-myc protein stability (Gregory and Hann, 2000) .
Increased amount of c-myc protein has been associated with point mutations, many of which were found to occur within the transactivation domain around Threonine 58 and Serine 62 (reviewed in Dang, 1999) . Importantly, these sites have also been implicated as target sites for myc phosphorylation by GSK3 and pp42/44 and pp54 MAPK (ERT/ERK) Seth et al., 1991; Henriksson et al., 1993; Lutterbach and Hann, 1994; Pulverer et al., 1994) and possibly JNK (Noguchi et al., 1999) . Phosphorylation of c-myc by MAPK promotes the stability of c-myc (Cheng et al., 1999; Sears et al., 1999 Sears et al., , 2000 , which correlates with myc-dependent gene activation and S phase induction (Sears et al., 1999) . Replacement of these residues with alanine results in decreased transactivation (Gupta et al., 1993) , altered transformation capability (Henriksson et al., 1993; Hoang et al., 1995) and increased c-myc half-life (Salghetti et al., 1999) by impairing proteasomemediated turnover (Bahram et al., 2000; Gavine et al., 1999; Gregory and Hann, 2000) .
In this study, we demonstrate that selective stress conditions such as TNFa and cycloheximide, which drive cells to apoptosis, increase c-myc steady-state levels. As these forms of stress signal through TRAF/ GCK/MEKK1 kinases (Shi and Kehrl, 1997; Baud et al., 1999) , we characterized the role of these kinases in the regulation of c-myc stability and identify a novel region of c-myc that is important in altering c-myc stability.
Results
To assess the eect of stress on myc stability, a number of physiological stress stimuli were evaluated for their eect on altering c-myc protein levels. An early passage of TIG-3, normal human lung ®broblasts, which express noticeable levels of endogenous c-myc protein and therefore allowed the monitoring of changes in response to stress, were used. TIG-3 cells were ®rst exposed to UV irradiation (UV-C; 254 nm) at dierent doses (6 or 30 J/m 2 ) and the level of endogenous c-myc protein was monitored at 0, 1, 2 and 4 h after treatment. Exposure to either a mild or high dose of UV caused a twofold increase after 1 ± 2 h, which declined back to basal levels within 4 h ( Figure 1a ). The rapid increase in c-myc protein levels seen after UV treatment coincides with the kinetics of activation of stress kinases following UV-irradiation. A similar increase in c-myc protein after 1 ± 2 h followed by a decrease after 4 h, was seen when cells were treated with UV-B (300 nm) at a low dose (150 J/cm 2 ; Figure  1c ) or high dose (450 J/cm 2 ; data not shown). To determine which of the stress signaling pathways is required for UV-induced accumulation of c-myc protein levels, we tested the ability of pharmacological inhibitors of dierent signaling kinase cascades, as well as transcriptional inhibitors, to attenuate the UVinduced accumulation of c-myc protein. Treatment with SB203580 which inhibits p38 activation (as demonstrated by inhibition of UV-induced phosphorylation of its ATF2 substrate while relative levels of ATF2 remain unchanged), and JNK activation (as demonstrated by inhibition of UV-induced phosphorylation of c-Jun while relative levels of c-Jun remained constant) in response to UV treatment, eciently abrogated UV-induced increase of endogenous c-myc (Figure 1b) . Interestingly, higher basal levels of the cmyc and c-Jun protein were seen after treatment with SB203580, probably due to indirect eects of this inhibitor (Figure 1b) . In contrast, neither inhibitor of the ERK pathway (PD98059) nor inhibitors of the JAK/STAT pathway (AG490) or tyrosine kinases (herbimycin A) were able to attenuate the UV-induced increase of steady-state levels of endogenous myc (data not shown). Actinomycin D treatment also attenuated UV-induced accumulation of c-myc, pointing to the role of transcription in accumulation of c-myc after UV exposure. These observations suggest that the increase in the steady-state levels of c-myc after UV-treatment is mediated by stress kinases via their transcription factor substrates, which induce c-myc transcription and consequently protein levels. This ®nding is in line with the observation that UV increases the level of c-myc mRNA levels (Blattner et al., 2000) .
Cytokine treatment using TNF (tumor necrosis factor)-a at two dierent concentrations did not induce signi®cant changes in c-myc protein levels within the time period in which NF-kB and SAPK are activated ( Figure 2a) . Treatment of the TIG-3 cells with cycloheximide, an inhibitor of protein synthesis, caused a ®vefold decrease in the steady-state levels of endogenous c-myc within 2 h (Figure 2b ), further illustrating the short half life of the c-myc protein.
The decrease in c-myc levels upon cycloheximide treatment also suggest that the contribution of stress kinases, which are also induced by this treatment, is via their eect on transcription factors that aect myc transcription, thereby explaining why inhibition of protein synthesis attenuates transcriptional upregulation and excludes their contribution to c-myc stability under these cellular conditions. However, the combination of TNFa and cycloheximide, which is often used Oncogene Stress-induced c-myc protein stability D Alarcon-Vargas et al to generate extreme stress conditions that yield massive cell death (Li et al., 1998) , not only attenuated the decrease seen upon cycloheximide treatment, but caused a sevenfold increase in c-myc expression levels ( Figure 2b ). These results suggest that selective forms of stress conditions eciently increase c-myc protein stability.
To characterize the signaling pathways which mediate the increase in c-myc levels, we tested stress kinases implicated in the response to extreme stress conditions such as those elicited by the combination of TNFa and cycloheximide. TNFa has been reported to signal to JNK and p38 by coupling TRAF2 (TNF receptor-associated factor) to mitogen-activated protein kinase/ERK kinase kinase 1 (MEKK1) and JNK via GCK (germinal center kinase) (Yuasa et al., 1998) . TNFa also activates MEKK1 via activation of receptorinteracting protein (RIP), which associates with and phosphorylates MEKK1 (Kim et al., 2001) . Activated RIP subsequently results in p38 activation (Yuasa et al., 1998) as well as the activation of I-kappab kinasebeta (IKKb), and can be blocked by a kinase-inactive form of MEKK1 (Kim et al., 2001) . We therefore used constitutively active forms of MEKK1 and its downstream eectors JNK, p38, and MEK. Co-transfection of 293T cells with c-myc and DMEKK1 (a constitutively active form of MEKK), but not TR-MEKK (a kinase-inactive form of MEKK1), results in a sixfold increase of c-myc protein levels (Figure 3a) . Expression of JNKK2-CAA (a constitutively active JNK kinase) or MEK-EL (a constitutive activator of the MAPK/ ERK pathway) resulted in about a fourfold increase of c-myc protein levels (Figure 3a ). These observations are in accord with studies that have demonstrated a role for the MEK/ERK pathway in promoting increased cmyc protein half-life (Cheng et al., 1999; Sears et al., 1999) . Similarly, expression of MKK 6 D/D (a constitutively active p38 kinase) led to a 2.5-fold increase in levels of c-myc (Figure 3a) . These MEKK1-inducible kinases led to an increase in c-myc steady-state levels comparable to that elicited by the proteasome inhibitor, MG132 (Figure 3a) . In contrast, expression of GSK 3b S9A (a constitutively active form) led to a 50% decrease in c-myc protein levels ; these inhibitors were added back to the cells after irradiation for 2 h before harvesting. To visualize c-myc protein levels, 80 mg of protein was loaded on a 10% SDS ± PAGE gel. Immunoblot was performed with c-myc polyclonal antibody (RDI). The blot was subsequently stripped and reprobed for phosphorylated-ATF2 to verify p38 kinase activity, and again for total ATF2 to con®rm equal loading; similarly, membrane (lower part) was probed for phosphorylated c-jun to check JNK activity and again for total c-jun to con®rm equal loading. ( Figure 3a ). These results suggest that stress-activated kinases eciently increase levels of c-myc expression, whereas kinases that are active under normal growth conditions limit c-myc expression levels. Since the accumulation of endogenous c-myc following UV-treatment was attenuated by actinomycin D, we have tested whether the increase seen upon expression of DMEKK1 could be also aected by inhibition of protein transcription. As shown in Figure  3b , actinomycin D treatment did not attenuate the increase in steady-state levels of c-myc observed after MEKK1 expression. This result suggests that the eect of MEKK1 truly re¯ects ability of stress conditions to increase steady-state levels of c-myc protein, similar to combined treatment of TNFa and cycloheximide. Accordingly, MEKK1 was used in subsequent studies, which were aimed at further characterization of altered c-myc stability in response to selective stress conditions.
To identify which of c-myc domains are required for its elevated expression in response to DMEKK1 signaling, we used a series of c-myc deletion mutants, each of which lacks about 60 amino acids of successive regions (WP Tansey, unpublished data; Figure 4a ). Forced expression of the dierent c-myc mutants with DMEKK1, but not TR-MEKK1 (the catalytically inactive form), identi®ed dierent domains of c-myc which are required to mediate an increase in the level of c-myc protein expression in the normal human lung ®broblasts TIG-3. The wild type as well as deletion mutant forms spanning amino acids 1 ± 126 (DA and DB) and 190 ± 378 (DD, DE, and DF) of c-myc retained the increase (4twofold) in c-myc protein levels upon DMEKK1 expression (Figure 4b ), suggesting that amino acids 1 ± 126 and 190 ± 378 are not required for MEKK1-mediated increased myc expression in TIG-3 cells. C-myc deleted of amino acids 379 ± 438 (DG) exhibited a 50% increase in levels after DMEKK1 overexpression in TIG-3 (Figure 4b ). The only mutant whose levels remained unchanged in response to DMEKK1 expression was myc deleted of amino acids 127 ± 189 (DC; Figure 4b) . Interestingly, the average basal levels of the DB, DC, DF and DG mutants were higher than the wt, DA, DD, or DE forms, suggesting that other factors which are expressed under normal growth conditions in TIG-3 cells are sucient to increase basal expression of c-myc, independent of amino acids 127 ± 189. MEKK1 retained the ability to increase steady-state levels of myc deleted of box II (Flinn et al., 1998) , which overlap some (a.a. 128 ± 144) of the residues deleted in the myc DC mutant (data not shown), suggesting that the region which mediates the increase in c-myc in response to MEKK1 signaling lies outside of box II. These observations identify a novel domain required for the regulation of c-myc by stress kinases.
To con®rm that the changes in myc levels seen following DMEKK1 expression can be attributed to changes in myc protein stability, we have performed pulse chase assays. To ensure ecient methionine incorporation, we used c-myc constructs tagged with a methionine-rich variant of HA (HAM; Herbst and Figure 3 MEKK1 and its downstream kinases, but not GSK3b, mediate a transcriptionally-independent increase in c-myc protein levels. (a) Cells were co-transfected with V5 epitope-tagged wild type c-myc (8 mg) and the constitutively active forms of the kinases indicated (400 ng). In all cases cells were also transfected with CMV-b-galactosidase (b-gal; 500 ng) to normalize the lysates per transfection eciency. b-gal normalized lysates were immunoprecipitated using a monoclonal antibody against the V5 epitope (Invitrogen), and immunoblot was carried out using cmyc polyclonal antibody (RDI). (b) TIG-3 cells were transfected with the indicated plasmids using lipofectamine (GIBCO): 2.5 mg of either mock, or HA-tagged myc forms indicated, 1 mg of TR-MEKK (catalytically inactive form of MEKK, 7lanes) or DMEKK1 (constitutive active kinase form, +lanes), and 0.5 mg CMV b-gal to assess transfection eciency. Two hours prior to harvesting, cells were treated with 2.5 mM actinomycin D or not. Lysates (500 mg) were immunoprecipitated using HA antibody.
Immunoblot was carried out using c-myc polyclonal antibody (RDI). Figure shown is representative of three or more experiments
Oncogene Stress-induced c-myc protein stability D Alarcon-Vargas et al Tansey, 2001 ). The half-life of the wild type c-myc protein when transfected alone ( Figure 5 ) or with TR-MEKK1 (data not shown) is about 20 min, similar to that which has been reported extensively for c-myc (Luscher and Eisenman, 1988; Waters et al., 1991; Gregory and Hann, 2000) . Co-transfection of c-myc with DMEKK1 extended the half-life of the protein to over 100 min ( Figure 5 ). In contrast, the half-life of myc DC, which was also around 20 min, was not altered upon expression of TR-MEKK1, or DMEKK1 ( Figure 5 and data not shown). This data supports the notion that the region of myc encompassing amino acids 127 ± 189 (deleted in c-myc C) is important for mediating MEKK1-induced stability of the c-myc protein.
Discussion
The data presented in this study provide new mechanistic insight for the regulation of c-myc stability under normal and stress growth conditions. First, we demonstrate that dierent forms of stress utilize alternate mechanisms to increase levels of c-myc via the activation of stress kinases. Whereas UV irradiation eciently increases steady-state levels of c-myc, this increase, which is dependent on the activation of p38 and possibly JNK, could be blocked by inhibitors of transcription. This ®nding suggests that the activation of stress kinases by UV contributes to transcriptional activation of the c-myc promoter, resulting in increased c-myc synthesis, which would be consistent with the ability of actinomycin D to block the increase in c-myc expression levels. The latter conclusion is also supported by the ®ndings that treatment with cycloheximide, which eciently induces the same stress kinases, also resulted in decreased levels of the c-myc protein. Thus, while required, p38 and JNK contribute to elevated levels of c-myc following UV-treatment at the transcriptional level, rather than via stabilization of the protein. The former is supported by the studies of Blattner et al. (2000) who demonstrated increased c-myc mRNA in response to UV-treatment. Among the transcription factors implicated in c-myc transcription which are regulated by stress kinases is NF-kB (Potter and Marcu, 1997) . In contrast to the eect of UV, the combined treatment of TNFa and cycloheximide, often used as a potent inducer of apoptosis and therefore referred to as an extreme stress condition, eciently increased steadystate levels of c-myc in a manner that could not be blocked by an inhibitor of protein translation. This ®nding suggests that selective stress conditions eciently increase c-myc protein stability. Increased levels of c-myc have been demonstrated to be an essential component of TNFa-induced apoptosis (Park et al., 1998) , further supporting the notion that changes monitored here represent a relevant mechanism for TNFa-mediated regulation of c-myc levels. Given that c-myc has also been implicated in promoting apoptosis (Askew et al., 1991; Evan et al., 1992; Thompson, 1998) , the mechanisms that underlie the regulation of c-myc stability, as illustrated here for MEKK1 and its related kinases, is expected to play a pivotal role in regulation of myc-dependent apoptosis. MEKK1 also represents the set of kinases reported to respond to extreme stress conditions such as TNFa combined with cycloheximide (Li et al., 1998; Yujiri et al., 1998) . Although high doses of UV used here also eciently cause apoptosis, the underlying cellular response is somewhat dierent to that induced following TNFa and cycloheximide treatment, thereby highlighting the regulation of myc expression by alternate mechanisms. Further studies will determine the stress responsive components that alter the balance between transcriptional and post-translational means to increase c-myc expression. The existence of alternate regulatory pathways is also expected to result in dierent kinetics and duration for altered c-myc expression. The present study further illustrates which of the cmyc domains is required for the stabilization seen following MEKK1 signaling. Data obtained with the dierent c-myc deletion mutants best illustrates the complex regulation of c-myc protein stability. Our ®ndings in this context led to several important observations. First, our data strongly suggest that neither box I nor box II are required for the regulation of c-myc protein stability by MEKK1, as deletion mutants lacking these domains were as responsive for MEKK1 eects. This data argues that the phosphorylation within the box I regions, that was formally reported to play an important role in the stabilization of c-myc (Salghetti et al., 1999; Gregory and Hann, 2000; Sears et al., 2000) , may serve another set of stimuli which utilizes a dierent subset of kinases.
The functional and physiological signi®cance of our ®ndings is best illustrated with the example of c-myc S, a form of the protein translated through a leaky scanning mechanism from a downstream AUG resulting in c-myc lacking the ®rst 100 amino acids, including box I, which exhibits comparable stability and is capable of eliciting many of the functional activities implicated for the full-length protein (Xiao et al., 1998; Chen et al., 2000) . Future studies will determine the role of MEKK1 and stress kinases in the stability of myc S and in acquiring its ability to elicit its activities. The mapping of phosphoacceptor sites within the novel domains identi®ed in the current study is also expected to better de®ne the cellular conditions under which selective stress conditions and corresponding kinases contribute to the stability and activities of wt and myc S forms. Figure 5 Increased c-myc stability by MEKK1 requires C domain of myc. U2OS cells were transfected with 250 ng of the indicated myc plasmids (cloned in the HAM vector) using Fugene6 (Roche-Boehringer Mannheim) Twenty-four hours post-transfection cells were pulse chased as described in`Materials and methods'. Lysates were subject to denaturing immunoprecipitation using the HA antibody, run on a 10% SDS ± PAGE gel, ®xed, treated with Amplify (Amersham), dried, and subject to autoradiography. Due to the multiple methionines in the HAM vector, several forms of the HAM-myc DC protein were immunoprecipitated with HA, perhaps due to the ability of this conformationally-dierent deletion mutant to be translated eciently from other upstream methionines. Comparative separation on SDS ± PAGE identi®ed the lowest band as that which truly re¯ects the HA-myc DC, which was used for analysis (indicated by the arrow). 
Materials and methods

Constructs
WT myc tagged with the V5 epitope was obtained from E Flinn (Flinn et al., 1998) . WT c-myc and respective deletion mutants of successive portions of about 60 amino acids (named DA-DG, Figure 3a) cloned in pCGN tagged with HA, which is under control of the CMV promoter (described elsewhere), and pCGN-HAM vector, a methionine-rich variant of the HA tag, was used in pulse-chase of wild type myc and myc DC (Herbst and Tansey, 2001) . DMEKK1 (constitutively active MEKK1 lacking amino acids 1 ± 351) and its catalytically inactive counterpart, TR-MEKK1 (K432M) were obtained from A Minden (Minden et al., 1994) . MEK-EL (constitutively active form of MEK1) in a pcDNA 3.0 vector is from S Aaronson. JNKK2-CAA (constitutively active JNKK2), MKK6 D/D (constitutively active MKK6) were kindly obtained from M Karin (Chen et al., 1998) . GSK3b, S9A (mutant active GSK3b) is from E Krebs (Eldar-Finkelman et al., 1996) .
Transfection
Transfection of normal human lung ®broblasts (TIG-3) with myc forms and TR-MEKK1 or DMEKK1 were carried out using lipofectamine (GIBCO). 293T, human adenovirustransformed kidney cells expressing SV40 large T antigen were transfected using calcium phosphate. In all cases, CMVbgalactosidase was added to monitor transfection eciency. U20S osteoblast cell line was transfected using Fugene6 (Roche-Boehringer Mannheim). Chemicals PD98059 (50 mM) was used to inhibit MEK; SB203580 (10 mM) was used to inhibit p38, and at the high dose (50 mM) to also inhibit JNK; AG490 (50 mM) was used to inhibit JAK (Calbiochem). Actinomycin D (2.5 mM) was used to inhibit transcription, and herbimycin A (1 mM) was used to inhibit tyrosine kinases (Sigma). MG132 (40 mM) was used to inhibit the 26S proteasome (Peptides International).
Stress treatments
TIG-3, normal human ®broblasts, were treated with the following stress forms and harvested at the timepoints indicated in results. Ultraviolet irradiation (UV-C; 254 nm) at low dose, 6 J/m 2 , or high dose, 30 J/m 2 . Ultraviolet irradiation (UV-B; 300 nm) at a low dose 150 J/cm 2 , or high dose, 450 J/cm 2 . Cycloheximide treatment (CHX) at 20 mg/ml (Sigma); tumor necrosis factor-alpha (TNF-a) at 5, 10 or 20 ng/ml; R&D systems) was used. Actinomycin D (ActD), 2.5 mM (Sigma) was used. Immunoblot was performed with cmyc polyclonal antibody (RDI). Cells were treated for 30 min prior to UV induction with the compounds listed under chemicals' in conditioned media: media was removed for UVC-treatment (30 J/m 2 ) and media with the inhibitors was added back for an additional 2 h post-UV induction.
Pulse-chase
U2OS cells were transfected with the indicated constructs using Fugene6 (Roche-Boehringer Mannheim). 24 h posttransfection, cells were starved of methionine and cysteine for 30 min then metabolically labeled with 35 S-labeled methionine (0.4 mCi) for 40 min (Amersham), followed by a chase using an excess of cold unlabeled 2 mM methionine and 2 mM cysteine, and collected either immediately after the label (0 min) or 20, 40 and 100 min after adding chase media. Denaturing immunoprecipitation with HA pulled down exogenous myc tagged with HAM (Herbst and Tansey, 2001) , followed by separation on a 10% SDS ± PAGE gel, ®xation with methanol/acetic acid, treatment with Amplify (Amersham) for 30 min before drying, and autoradiography. Phosphoimage signals were quanti®ed using Quantity One program (Biorad).
Western blots
Immunoprecipitation with HA antibody (Babco) and Western blot with myc polyclonal antibody (RDI) was performed for TIG-3 cells. Immunoprecipitation with V5 antibodies (Invitrogen) and Western blotting with myc polyclonal antibodies was performed for 293T cells. Immunoprecipitation with HA antibody (Babco) and autoradiography was used for U2OS pulse chase. Endogenous c-myc from TIG-3 and U2OS cells was probed using c-myc polyclonal antibody (RDI). b-actin monoclonal antibody (Sigma) was used to con®rm equal protein loading. Phospho-ATF2 antibodies were from Calbiochem. Control ATF2 antibodies, phosphoc-jun antibodies, and control c-jun antibodies were from Cell Signaling Technologies. Quantitation of the density of bands was performed using the Quantity One program (Biorad).
